25 RECREATION PARK DR SUITE 108, HINGHAM, MA
Reports Over 100% Revenue and Customer Growth as Procedure Volume also Rises in the Second Quarter of 2026
Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with a Global Manufacturing Leader
Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence